Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Phase 3

Shire

Atomoxetine Hydrochloride
Guanfacine